KEYTRUDA® (Pembrolizumab)

The FDA on March 21, 2022, approved KEYTRUDA® (Pembrolizumab) as a single agent, for patients with advanced endometrial carcinoma that is MicroSatellite Instability-High (MSI-H) or MisMatch Repair deficient (dMMR), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting, and who are not candidates for curative surgery or radiation. KEYTRUDA® is a product of Merck & Co., Inc.